Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

A myriad of pathways to NASH.

Larrain S, Rinella ME.

Clin Liver Dis. 2012 Aug;16(3):525-48. doi: 10.1016/j.cld.2012.05.009. Epub 2012 Jun 26. Review.

PMID:
22824479
2.

Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.

Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC.

J Gastroenterol Hepatol. 2012 Feb;27(2):341-50. doi: 10.1111/j.1440-1746.2011.06939.x.

PMID:
21929649
3.

Etiopathogenesis of nonalcoholic steatohepatitis.

Chitturi S, Farrell GC.

Semin Liver Dis. 2001;21(1):27-41. Review.

PMID:
11296694
4.

Drug-induced steatohepatitis.

Stravitz RT, Sanyal AJ.

Clin Liver Dis. 2003 May;7(2):435-51. Review.

PMID:
12879993
5.

[Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].

Korenaga M, Kawaguchi K, Korenaga K, Uchida K, Sakaida I.

Nihon Rinsho. 2006 Jun;64(6):1157-64. Review. Japanese.

PMID:
16768125
6.

Current pharmacological treatment of nonalcoholic fatty liver.

Portincasa P, Grattagliano I, Palmieri VO, Palasciano G.

Curr Med Chem. 2006;13(24):2889-900. Review.

PMID:
17073635
7.

Drugs and steatohepatitis.

Farrell GC.

Semin Liver Dis. 2002;22(2):185-94. Review.

PMID:
12016549
8.

[Nonalcoholic fatty liver disease].

Ko JS.

Korean J Gastroenterol. 2010 Jul;56(1):6-14. Review. Korean.

9.

Nonalcoholic steatohepatitis and the metabolic syndrome.

Jiang J, Torok N.

Metab Syndr Relat Disord. 2008 Mar;6(1):1-7. doi: 10.1089/met.2007.0026. Review.

PMID:
18370830
10.

Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it.

Begriche K, Igoudjil A, Pessayre D, Fromenty B.

Mitochondrion. 2006 Feb;6(1):1-28. Epub 2006 Jan 5. Review.

PMID:
16406828
11.

Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.

Liew PL, Lee WJ, Lee YC, Wang HH, Wang W, Lin YC.

Obes Surg. 2006 Dec;16(12):1584-93.

PMID:
17217634
12.

[Metabolic syndrome and the liver (NAFLD/NASH)].

Hůlek P, Dresslerová I.

Vnitr Lek. 2009 Jul-Aug;55(7-8):646-9. Czech.

PMID:
19731869
13.

A fresh look at NASH pathogenesis. Part 1: the metabolic movers.

Larter CZ, Chitturi S, Heydet D, Farrell GC.

J Gastroenterol Hepatol. 2010 Apr;25(4):672-90. doi: 10.1111/j.1440-1746.2010.06253.x. Review.

PMID:
20492324
14.

Evolving trends in nonalcoholic fatty liver disease.

Delgado JS.

Eur J Intern Med. 2008 Mar;19(2):75-82. doi: 10.1016/j.ejim.2007.02.034. Review.

PMID:
18249301
15.

From the metabolic syndrome to NAFLD or vice versa?

Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G.

Dig Liver Dis. 2010 May;42(5):320-30. doi: 10.1016/j.dld.2010.01.016. Epub 2010 Mar 6. Review.

PMID:
20207596
16.

Nonalcoholic fatty liver disease in severely obese subjects.

Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP.

Am J Gastroenterol. 2007 Feb;102(2):399-408.

PMID:
17311652
17.

Present and future therapeutic strategies in non-alcoholic fatty liver disease.

Calamita G, Portincasa P.

Expert Opin Ther Targets. 2007 Sep;11(9):1231-49. Review.

PMID:
17845148
18.

Insulin resistance in nonalcoholic fatty liver disease.

Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G.

Curr Pharm Des. 2010 Jun;16(17):1941-51. Review.

PMID:
20370677
19.

Nonalcoholic fatty liver disease: from steatosis to cirrhosis.

Farrell GC, Larter CZ.

Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112. Review.

PMID:
16447287
20.

Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity.

Liew PL, Lee WJ, Wang W, Lee YC, Chen WY, Fang CL, Huang MT.

Obes Surg. 2008 Jul;18(7):847-53. doi: 10.1007/s11695-007-9355-0. Epub 2008 May 6.

PMID:
18459024
Items per page

Supplemental Content

Write to the Help Desk